Pathology Report — Definitive Cancer Analysis

A pathology report is structured into distinct clinical sections designed to provide a comprehensive analysis of a specimen. The document begins with clinical details and the gross description, which records the physical dimensions, weight, and visual appearance of the resected tissue. Next, the microscopic description details cellular architecture, nuclear abnormalities, mitotic rate, and evidence of lymphovascular or perineural invasion.

The definitive conclusion appears in the diagnosis section, which states the specific cancer subtype and histological grade. The report also documents the status of surgical margins—specifying whether the outer boundaries of excised tissue are clear of neoplastic cells—and provides TNM staging parameters. In modern oncology, an addendum frequently incorporates molecular diagnostic findings, such as gene mutations or protein overexpression.

The pathology report represents the single most important diagnostic record in your oncology chart. It removes clinical uncertainty by confirming the true nature of the illness. Without this document, clinicians cannot accurately determine cancer stage, select appropriate medications, or predict potential outcomes. It also establishes whether additional surgery is needed to achieve clear borders and reveals which targeted therapies might be effective against the tumour.

The report integrates results from histological examination using chemical dyes, immunohistochemical (IHC) profiling, and molecular testing. Notable elements assessed include hormone receptor status (ER/PR), HER2 gene amplification, KRAS or BRAF mutations, mismatch repair (MMR) proteins, and tumour mutational burden (TMB).

Pathology reports are generated for all suspected solid tumours and haematological disorders, including breast ductal carcinomas, colorectal adenocarcinomas, cutaneous melanomas, renal cell carcinomas, thyroid nodules, and lymph node biopsies evaluated for potential Hodgkin or non-Hodgkin lymphomas.

Report findings directly govern clinical management. Tumours with positive margins may require further surgery or localised radiotherapy. High histological grades or positive lymph nodes often justify systemic adjuvant chemotherapy. Identified molecular alterations guide the prescription of targeted oral inhibitors or immune checkpoint therapies.